<img src="https://cdn.it.bgi.com/source/article+first+photo.jpg" alt="article+first+photo.jpg" data-href="" style=""/>First linked to mutations in the CHD7 gene in 2004, CHARGE syndrome is a rare genetic disorder occurring in approximately 1 in 8,500 to 15,000 births. According to <a href="https://www.ncbi.nlm.nih.gov/books/NBK559199/" target="_blank">National Institute of Health (NIH)</a>, CHARGE syndrome is an acronym for coloboma of eyes (C), heart disease (H), atresia of the choanae (A), retarded growth and mental development (R), genital anomalies (G), and ear malformations and hearing loss (E). Diagnosis is often challenging because this disorder manifests differently across individuals. A recent study published in <a href="https://onlinelibrary.wiley.com/doi/10.1002/ccr3.8670" target="_blank">Clinical Case Reports</a> explored the detection of CHARGE syndrome through prenatal ultrasound observations of fetal ear abnormalities. Spearheaded by Yu Liang from Shijiazhuang Fourth Hospital and Sijie He, a specialized scientist from BGI Genomics, this research underscores the crucial role of early genetic screening and prenatal diagnostics. Case Background and Research MethodA pregnant woman, expecting her second child but with no previous live births, visited Shijiazhuang Fourth Hospital for a prenatal check-up. Ultrasound scans were performed at weeks 22, 28, 33, and 35 of the pregnancy. The initial detection of an abnormal ear shape at 22 weeks gestation prompted suspicions of CHARGE syndrome. However, the pregnant woman declined invasive prenatal testing after genetic counselling. After birth, comprehensive assessments, including physical exams and whole exome sequencing, confirmed the diagnosis. Key Findings<ol><li>Potentially Difficult to Diagnose: The CHD7 mutation is not listed in the public Genome Aggregation Database and has been predicted to be harmful by renowned genetic analysis tools like CADD and Mutation Taster. Without genetic testing, it is difficult to determine the condition during pregnancy and even after birth. In this case, the parents declined further invasive prenatal testing. Due to the absence of other significant supporting evidence, it was difficult to confirm the CHARGE syndrome through ultrasound alone. </li><li>Phenotypes vary: The phenotypes were highly variable, and no clear correlation has been found between the severity of the phenotype and mutations in specific domains of the CHD7 protein. Despite a month of nutritional support, the disease continued to progress. Eventually, the parents refused any curative treatment and allowed for only supportive care.</li><li>Mostly De Novo, Sometimes Inherited: To confirm a suspected genetic disorder, Trio-Whole-Exome Sequencing (Trio-WES) were applied on the newborn and the parents. The test revealed a nonsense mutation chr8-61,654,397-C-T (GRCh37/hg19) in CHD7 gene (ENST00000524602 c.406C &gt; T, p.Q136X in exon 2) of the newborn, which was absent in the parents. This particular mutation is likely to cause an early disruption in protein formation, potentially leading to significant functional impairments as outlined by American College of Medical Genetics and Genomics (ACMG) mutation interpretation guidelines. </li></ol> <img src="https://cdn.it.bgi.com/source/image869.png" alt="image869.png" data-href="" style="width: 100%;"/>Sanger sequencing results. Trio-WES genetic analysis revealed that the newborn has a nonsense mutation, while this mutation was not found in the parents. The specific location of the mutation is clearly indicated by arrows in the results. The Importance of Early DiagnosisCHARGE syndrome, a congenital anomaly with a high mortality rate, underscores the importance of early prenatal diagnosis for effective management. The researchers recommend conducting ultrasound exams between the 20th and 24th weeks of pregnancy to detect fetal ear abnormality. If any irregularities in the ear's shape, size, or position are detected, a specialized genetic test for the CHD7 gene associated with rare diseases should be carried out to confirm the diagnosis. This approach provides a window for timely interventions and enhances our understanding of rare genetic conditions, improving future diagnostic protocols.Sijie He, specialized scientist, BGI Genomics, further advises, “For cases where abnormalities are found during ultrasound examination during pregnancy, it is recommended that pregnant women receive genetic counselling, prenatal diagnosis and genetic testing to confirm the diagnosis, which can effectively control birth defects.” Introducing BGI Genomics XOME cWES<a href="https://www.bgi.com/global/service/monogenic-disease-panel" target="_blank">cWES</a> is intended for use in conjunction with the clinical presentation and other markers of disease progression for the management of patients with rare genetic disorders and especially heterogeneous phenotypes. cWES sequences over 180,000 exons across 22,000 genes for more than 4,000 monogenic diseases. About BGI GenomicsBGI Genomics, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange. Read more: <a href="https://www.bgi.com/global/news/advancing-newborn-genetic-screening-through-prenatal-carrier-screening" target="_blank">Advancing Newborn Genetic Screening Through Prenatal Carrier Screening</a><a href="https://www.bgi.com/global/news/enhancing-high-risk-infant-outcomes-with-newborn-genetic-screening-in-china" target="_blank">Enhancing High-risk Infant Outcomes with Newborn Genetic Screening in China</a>

Study Reveals How Fetal Ear Shape Could Signal Rare Genetic Condition | BGI Insight

On April 30, BGI Genomics and the Rwanda Biomedical Centre (RBC) launched a cervical cancer screening program in Ngoma District, Eastern Province, Rwanda. This program will provide 20,000 Human papillomavirus (HPV) DNA tests for local women, aiming to enhance cervical cancer screening and prevention efforts and improve local precision medical testing capabilities. The launching event was attended by Wang Xuekun, Chinese Ambassador to Rwanda; Mr. Pudence Rubingisa, Governor of Eastern Province; Nathalie Niyonagira, the Mayor of Ngoma District, Rwanda; Dr. Albert Tuyishime, Head of Department, (HDPC) HIV/AIDS Diseases Prevention and Control, RBC; Dr. Theoneste Maniragaba, Director of the Cancer Diseases Unit at the RBC; Du Yutao, Chief Operating Officer of BGI Genomics; and Gao Zhiqiang, Commercial Counsellor of the Chinese Embassy in Rwanda, among others.<img src="https://cdn.it.bgi.com/source/050124chineseambassadorresized.jpg" alt="050124chineseambassadorresized.jpg" data-href="" style="">Wang Xuekun, Chinese Ambassador to RwandaWang Xuekun, Chinese Ambassador to Rwanda, stated: "BGI Genomics is a leading enterprise in the genomic industry, both in China and globally. The company has significantly contributed to promoting the friendship between China and Rwanda and advancing Rwanda's medical and health industry." <img src="https://cdn.it.bgi.com/source/050124pudence1resized.png" alt="050124pudence1resized.png" data-href="" style="">Mr. Pudence Rubingisa, Governor of Eastern ProvinceMr. Pudence Rubingisa, Governor of Eastern Province, commented, "We deeply appreciate our collaboration with BGI Genomics and other partners. As we initiate this project, we are dedicated to leveraging all available resources, including our local health workers and agencies, to facilitate effective screening, awareness, and educational efforts. This initiative is pivotal for enhancing the well-being of our community."<img src="https://cdn.it.bgi.com/source/050124dralbertresized.jpg" alt="050124dralbertresized.jpg" data-href="" style="">Dr. Albert Tuyishime, Head of the HIV/AIDS Disease Prevention and Control Department at RBCDr. Albert Tuyishime, Head of the HIV/AIDS Disease Prevention and Control Department at RBC, remarked, "Cervical cancer is a major global challenge, particularly in developing countries with limited treatment options. Rwanda aims to lead the way in achieving the global cervical cancer elimination goals. We value our collaboration with BGI Genomics, which has enhanced screening services in the Ngoma district, and look forward to extending these services across the country."As Rwanda's public health implementation agency, the RBC is committed to enhancing local public health through scientific research, diagnostic services, and innovative healthcare interventions. For this initiative, BGI Genomics provides a comprehensive solution comprising laboratory equipment and technology transfer, while all project samples and testing data are handled by Rwanda's personnel and stored locally under local laws and regulations. The company will also assist in further upgrading the local closed-loop management system from cervical cancer screening to positive intervention, significantly enhancing Rwanda's healthcare infrastructure. The Chinese medical team assisting Rwanda provides support for the implementation of the cervical cancer screening project, and the team's leader Zhang Heping also attended the launching ceremony.Cervical cancer ranks as the second most prevalent cancer among women in Rwanda. According to data from the Rwanda Health Management Information System (HMIS), only 24% of eligible women in Rwanda have undergone cervical cancer screening in the past five years.According to <a href="https://www.who.int/publications/i/item/9789240030824" target="_blank">WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention</a>, HPV DNA testing, with an accuracy rate of up to 95%, is the first-choice screening method for cervical cancer screening. A self-sampling model is recommended, whereby women collect their test samples, followed by centralized testing. <img src="https://cdn.it.bgi.com/source/050124yutaoresized.png" alt="050124yutaoresized.png" data-href="" style="">Dr. Du Yutao, Chief Operating Officer of BGI Genomics"In China, HPV DNA testing technology has been applied in many large-scale public health service programs and achieved remarkable results. We hope that cervical cancer screening can leverage BGI Genomics technology and self-sampling model in countries worldwide and help accelerate the goal of eliminating cervical cancer worldwide," said Dr. Du Yutao, Chief Operating Officer of BGI Genomics. BGI Genomics self-developed HPV DNA testing products are suitable for large-scale population screening and precise HPV genotyping. A single test can screen for the 14 high-risk HPV types highly correlated with the occurrence of cervical cancer as per WHO guidelines and is validated by large-scale clinical data to be suitable for self-sampling.<img src="https://cdn.it.bgi.com/source/050124localpersonnelresized.png" alt="050124localpersonnelresized.png" data-href="" style="">Local personnel provide training to eligible women on the proper techniques for self-sampling.A self-sampling model requires only a few medical staff to facilitate the rapid collection of many samples, which significantly enhances accessibility and effectively enables screening to cover areas with limited medical resources. Notably, this approach offers considerable advantages in remote regions of developing countries where cold chain logistics are inadequate, as it minimizes the necessity for advanced transportation and storage infrastructure. The ease of use, convenience, and privacy will further enhance screening coverage.In the future, BGI Genomics plans to deliver advanced genetic testing technologies for reproductive health, tumor screening, and the prevention and control of infectious diseases in Rwanda. This will promote the overall capacity and efficacy of precision medicine and help upgrade the local medical and healthcare systems. About BGI Genomics and SENTIS HPV TestsBGI Genomics, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.The CE-certified <a href="https://www.bgi.com/global/service/bgi-sentistm-hpv-test" target="">SENTIS</a>&trade; HPV test combines self-sampling technology and genotyping assay to detect 14 most important, "high-risk" types of HPV, including HPV -16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 and 2 "low-risk" types of the virus, HPV -6, 11.

BGI Genomics’ First African Public Health Initiative: Supporting Cervical Cancer Screening for 20,000 Rwandans 

<img src="https://cdn.it.bgi.com/source/image578.png" alt="image578.png" data-href="" style=""/>The 19th International Conference on Genomics Thailand part (ICG-19-THA) will be held at the Chulalongkorn University in Bangkok on May 18th and 19th, 2024. The ICG-19-THA will continue to uphold the spirit of the Human Genome Project (HGP) - "Owned by All, Done by All, Shared by All", advocating for global and human-wide sharing, especially promoting international cooperation among developing countries. The upcoming conference is set to be significant, covering sessions such as "Challenges and Recommendations in Establishing National Genomics Projects for Health," "Rare Disease," "Cancer Genomics," and "Traditional Medicine." In addition to the traditional sessions of the ICG, the conference will also feature an intriguing forum - Transformation and Application in Longevity. We have invited numerous experts in this field, including Assistant Professor Vincenzo Sorrentino from the Department of Biochemistry &amp; Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, NUS, Professor Alexey Moskalev from the Institute of Biogerontology of Lobachevsky State University, and Professor Guanghui Liu from the Chinese Academy of Medical Sciences, among others. They will be making their first appearance in Thailand, guiding us in delving into the topic of anti-aging and exploring effective strategies to address the challenges of human aging. 1. InformationDate: May 18-19, 2024Theme: Omics, Wellness and LongevityVenue：Chulalongkorn University, ThailandLanguage: EnglishExpected Audience: 300 2. OrganizersCo-organizers:<ul><li style="text-align: justify;">Ministry of Higher Education,Science, Research and Innovation,MHESI </li><li style="text-align: justify;">Faculty of Medicine-Chulalongkorn University</li><li style="text-align: justify;">BGI Group</li><li style="text-align: justify;">Bangkok Genomics Innovation PCL (BKGI)</li><li style="text-align: justify;">Harvard Business Review</li><li style="text-align: justify;">Bumrungrad International Hospital &amp; VitalLife Scientific Wellness Center</li><li style="text-align: justify;">ThaiOmics</li></ul> Full Operating:<ul><li style="text-align: justify;">Hangzhou Bictimes Culture and Technology Co., Ltd</li></ul> 3. CommitteeChair of the Organizing Committee &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Huanming YANGChair of the Academic Committee &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Siqi LIUExecutive Chair of the Organizing Committee &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Ye YINCo-chairs of the IIAB ( International Independent Advisory Board) &nbsp; Fred DUBEE Lars BOLUNDCo-chairs of the ICG-19-THA &nbsp;Fred DUBEEVorasuk SHOTELERSUKNattiya HIRANKARNCo-chairs of the Transformation and Application in LongevityGuanghui LIU 4. Program<img src="https://cdn.it.bgi.com/source/image076.png" alt="image076.png" data-href="" style="width: 50%;"> <img src="https://cdn.it.bgi.com/source/image490.png" alt="image490.png" data-href="" style="width: 50%;"> 5. Moderators and Speakers (In alphabetical order of speakers' last names)<img src="https://cdn.it.bgi.com/source/image740.png" alt="image740.png" data-href="" style="width: 50%;">Continuously updated... 6. WebsiteThe ICG-19 website is now officially online, visit <a href="https://icg.bio/icg19" target="_blank">https://icg.bio/icg19.</a>More information will be updated soon. Stay tuned for the most recent updates.<img src="https://cdn.it.bgi.com/source/image591.png" alt="image591.png" data-href="" style="width: 30%;">Scan or long press the QR code to log in. 7. Registration7.1 Registration Fee Standards<table style="width: auto;"><tbody><tr><td colSpan="1" rowSpan="1" width="130">Type</td><td colSpan="1" rowSpan="1" width="156">Early bird price Before May 18</td><td colSpan="1" rowSpan="1" width="139">On-site Registration fee</td></tr><tr><td colSpan="1" rowSpan="1" width="130">Standard</td><td colSpan="1" rowSpan="1" width="156">999 CNY 5000 THB 138 USD</td><td colSpan="1" rowSpan="1" width="139">1099 CNY 5500 THB 152 USD</td></tr><tr><td colSpan="1" rowSpan="1" width="130">Student</td><td colSpan="1" rowSpan="1" width="156">499 CNY 2500 THB 69 USD</td><td colSpan="1" rowSpan="1" width="139">599 CNY 3000 THB 83 USD</td></tr><tr><td colSpan="3" rowSpan="1" width="426">*Note: Students enjoy a 50% discount with a Student ID.</td></tr></tbody></table> 7.2 Payment7.2.1 Alipay or WeChat Pay<img src="file:////private/var/folders/49/4t0tpyrs5rb21dxwbd8g8k800000gp/T/com.kingsoft.wpsoffice.mac.global/wps-keithlam/ksohtml//wps5.png" alt="" data-href="" style=""> <img src="https://cdn.it.bgi.com/source/image554.png" alt="image554.png" data-href="" style="width: 30%;">Please scan the QR code above to pay the registration fee 7.2.2 THB or USD（Bank Transfer）<img src="https://cdn.it.bgi.com/source/image286.png" alt="image286.png" data-href="" style="width: 30%;"> Please scan the QR code above to pay the registration fee*Remittance Note: Please scan the QR code to proceed with payment registration and fill in and upload the relevant information. 7.2.3 Please note：(1) The registration time is based on the actual payment time, and the on-site payment is based on the on-site payment price.(2) Participants who have paid the fee and are unable to attend the conference for any reason, please apply to the conference organizer. The remaining balance will be refunded after deducting 200 CNY/1005 THB/28 USD handling fee.(3) Invoice issuance and collection: Pay attention to check the electronic invoice through the registered email address before and after 10 working days after the successful payment, and the invoice for on-site registration will be issued within 15 working days after the meeting.(4) The registration fee includes 2-day lunch. Transportation and accommodation costs are at your own expense. 8. Hotel and TransportationAll participants and exhibitors are responsible for their own accommodation and transportation expenses. Hotel rooms are limited, so exhibitors are advised to book in advance.Recommended hotels around the venue: NO1. The Sukhothai Bangkok Hotel（Conference Agreement Hotel）Contact Person: JackPhone number: +0645245645Email: <a href="Thanadej.i@sukhothai.com" target="_blank">Thanadej.i@sukhothai.com</a>Note: Please contact the hotel manager, inform them of your participation in the 19th Genomics Conference, and send the payment information to the email to enjoy the conference hotel discount.Address: 13/3 S Sathon Rd, Khwaeng Thung Maha Mek, Khet Sathon, Krung Thep Maha Nakhon 10120, Thailand.<img src="https://cdn.it.bgi.com/source/image948.png" alt="image948.png" data-href="" style="width: 50%;"> NO2. Novotel Bangkok on Siam SquareContact Information: +66-2-2098888Address: 392, 44 Siam Square Soi 6, Khwaeng Pathum Wan, Pathum Wan, Krung Thep Maha Nakhon 10330, Thailand.<img src="https://cdn.it.bgi.com/source/image517.png" alt="image517.png" data-href="" style="width: 50%;"> NO3. Crowne Plaza Bangkok Lumpini Park, an IHG HotelContact Information: +66-2-6329000Address: 952 Rama IV Rd, Khwaeng Suriya Wong, Khet Bang Rak, Krung Thep Maha Nakhon 10500,Thailand.<img src="https://cdn.it.bgi.com/source/image017.png" alt="image017.png" data-href="" style="width: 50%;"> 9.Contact UsFor more information about registration, invoicing, exhibition and participation, please contact: <a href="icg19@bictimes.cn" target="_blank">icg19@bictimes.cn</a>

The Second Announcement of the ICG-19-THA

The rapid adoption of AI and big data technologies in the biotechnology sector presents unique data privacy and security challenges. To meet these challenges, BGI Genomics actively maintains certifications like ISO/IEC 27001 and BS 10012 while complying with rigorous regulatory standards, including GDPR.<img src="https://cdn.it.bgi.com/source/gdpr721.png" alt="gdpr721.png" data-href="" style=""/>ISO/IEC 27001 is a comprehensive framework that dictates the requirements for an information security management system (ISMS), essential for protecting a company's financial data, intellectual property, and personal details entrusted by third parties. Meanwhile, BS 10012 specifically addresses the management of personal data, aligning with the stringent requirements of data protection regulations such as the GDPR.In an insightful interview with <a href="https://www.news-medical.net/news/20240426/Achieving-and-maintaining-ISO-27001-and-BS-10012-certifications.aspx" target="_blank">AZoMedical</a>, Dr. Fu Wei, Director of Quality Management at BGI Genomics, details the systematic and exhaustive process behind these certifications. This includes comprehensive audits involving document reviews, site visits, and management interviews, emphasizing the company's ongoing commitment to excellence and security.<img src="https://cdn.it.bgi.com/source/Fu+Wei.png" alt="Fu+Wei.png" data-href="" style=""/>BGI Genomics integrates quality management and privacy security into its operations, continuously updating its practices to adhere to the latest changes in ISO/IEC 27001, BS 10012, and GDPR regulations. Dr. Fu emphasizes the firm's strict adherence to these standards, stating, “BGI Genomics strictly follows the standards to set up and maintain information security and privacy management systems. The certification organizations review BGI Genomics's management systems on-site annually to ensure they work and continue to meet the standards and criteria.”The impact of these certifications extends beyond meeting legal obligations; they foster enhanced trust with clients and partners. BGI Genomics updated its privacy policy and cookie policy earlier in the year. Its 2024 work plan includes significant updates to its information security management system. backup protocols for electronic records, and permission management for shared disks. &nbsp;About Dr. Fu WeiDr. Fu Wei is the Director of the Quality Management Department at BGI Genomics. In 2018, the Shenzhen Association for Quality recognized him as a person of outstanding quality. He helped the BGI Europe laboratory in Denmark achieve ISO 15189 and ISO/IEC 27001 certifications. About BGI Genomics<a href="https://www.bgi.com/global" target="_blank">BGI Genomics</a>, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 3,000 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.

Navigating the Complexities of Data Security  in Biotechnology | BGI Perspectives

First published on: <a href="https://communities.springernature.com/posts/microbiome-signatures-of-old-and-young-onset-colorectal-cancer" target="">Springer Nature</a>The author, <a href="https://www.linkedin.com/in/youwen-owen-qin-47b8aa5a/" target="_blank">Youwen Qin</a>, is a Research Scientist at BGI Genomics Shenzhen.The rising incidence of young-onset sporadic colorectal cancer (CRC) is a global concern. Leveraging a substantial number of deep sequencing metagenomes, our study shows striking similarities in gut microbial patterns at both taxonomic and selected gene marker levels between yCRC and old-onset CRC.This is my first research paper following my PhD training with Prof. Michael Inouye and Prof. Kathryn Holt in Melbourne and Cambridge.My research journey with CRC microbiome traces back to 2012 when I collaborated with Prof. Jun Yu and found bacterial taxa and functional genes associated with CRC. Since then, the field has progressed fast, with well-established associations between CRC and gut microbiome. However, few studies have delved into the gut microbiome concerning yCRC (aged &lt;50), partly due to its lower incidence rate compared to old-onset CRC (oCRC, aged ≥50).The gut microbiome is known to vary with age. With phenotypic differences in disease stage and tumor location between yCRC and oCRC, one could hypothesize that the gut microbiome might also differ. Aiming to characterize the gut microbiome of yCRC, I collaborated with Prof. Pei-Rong Ding at Sun Yat-Sen University Cancer Center since 2021.Negative findingsIn our study we conducted deep metagenomic sequencing on stool samples collected from a sizable cohort of CRC patients, including 167 yCRC. By comparing microbiome compositions between yCRC and oCRC, we observed only a few bacterial taxa that met the statistically significant threshold. Notably, the associations between age and microbial features across all studied samples were weak. Despite our rigorous efforts involving various analytical strategies, such as comparing individuals aged &lt;40 to those aged &gt;60, our investigations failed to yield promising results.The Fudan StudyWhile we were disappointed, a study by Yang et al. from Fudan University working on the same topic was published. They reported distinct signatures of yCRC relative to oCRC. We got even more disappointed. After thoroughly reviewing the Fudan paper multiple times, I found that their findings on oCRC weren't corroborated by other studies. One possible explanation is that their results primarily relied on 16S rRNA sequencing, although they were validated by shotgun metagenomic sequencing. Fortunately, the Fudan team also made the shotgun metagenomic sequencing (raw) data publicly available for 200 individuals. I downloaded and analyzed this data using our pipeline. Surprisingly, my findings diverged from those reported in the original paper. Notably, I found several well-known CRC-associated bacteria (Clostridium symbiosum, Hungatella hathewyi, Peptostreptococcus stomatis and Parvimonas micra) that were enriched in both oCRC and yCRC. Encouraged by these promising findings, we integrated our data with the Fudan one, along with other published datasets, ultimately uncovering consistent signatures for both oCRC and yCRC.Editor's SupportThen we found ourselves in a challenging position: eager to publish our results but needing more confidence in presenting contrasting findings to a previously published study. Despite our reservations, we decided to take a chance. I reached out to Dr. Javier Martinez-Vesga to discuss our intention to write a short paper detailing our contrasting results to a study published in Nature Communications. Interestingly, Javier suggested that we expand our scope and submit a full research article instead, highlighting the new data we had generated from numerous CRC patients.Reviewers' SupportDuring the peer-review process, we received positive feedback from all reviewers, who recommended conducting a more in-depth analysis of the bacterial genomes and exploring bacterial toxin and virulence factors. Following their suggestions, we conducted a more focused analysis, leading us to uncover insights into well-known CRC-associated taxa with clear pathogenic pathways: Fusobacterium nucleatum, Bacteroides fragilis, and Escherichia coli.Story of F. nucleatumIn our studied samples, we detected both F. nucleatum (Fn) and its close relative F. animalis (Fa; also known as Fn subspecies animalis, Fna). Strikingly, Fa had higher abundance and prevalence compared to Fn. This observation coincided with a very recent study published in Nature, which reported the enrichment of a distinct Fa clade in CRC niche, consistent with an earlier study. Moreover, in our Chinese cohort, we found no differentiation in the presence of the fadA gene (encoded adhesion protein A, which mediates Fn attachment to and invasion of host epithelial cells) between samples enriched with either Fn or Fa.Story of B. fragilisWe identified two distinct clusters of B. fragilis in our data. In line with a previous study, each individual was dominated by one strain. Pathogenic B. fragilis strains can produce enterotoxin, which plays a role in cell cycle regulation. While the specific identities of these two strain clusters were unknown to us, we observed differential abundance and prevalence of the enterotoxin-encoding gene but between the two clusters.Story of E. coliOnly one strain cluster of E. coli was identified in our samples. As a commensal bacterium in the gut, most E. coli strains are non-pathogenic. However, pathogenic strains often harbor the pks genomic island, which encodes colibactin, a compound implicated in DNA damage. Subsequently, we examined the relationship between the abundance of E. coli and pks. Interestingly, we observed a positive association in the Guangzhou cohort, but no correlation was evident in the Fudan cohort. This population heterogeneity implies a complex microbiome background of CRC across different geographic regions.Potential impactThe shared microbiome signatures between yCRC and oCRC could serve as a foundation for developing microbiome-based diagnostic methods for CRC screening. Our study showed that microbiome-based classifiers trained for oCRC had similar prediction performance for yCRC, and viceversa. The consistency in signatures across CRC cases of different ages suggests that the microbiota may play a pivotal role in CRC carcinogenesis.Ongoing workOne of the most intriguing questions is whether these microbial signatures correlate with CRC clinical outcomes. To address this, we are actively collecting follow-up data for many of the patients included in our study and investigating the relationship between gut microbiome and CRC outcomes. Since many CRC-associated bacteria are commonly found in the oral cavity, we have also generated matched metagenomes from saliva/tongue samples for most of our patients. It's worth noting that our current study only focused on bacterial taxa. However, considering that fungal and viral signatures have also been reported to be associated with CRC, conducting further analyses on fungi and viruses will offer new biological insights into CRC pathogenesis.Simultaneously, BGI Genomics is embarking on a mission to sequence 10 million microbiome samples as part of a large-scale cancer screening project for CRC. This endeavor will yield an unprecedented volume of microbiome data for humans. Science thrives on collaboration, and I extend a warm invitation to researchers worldwide to join us in deciphering this vast dataset and harnessing its potential for the greater good.About BGI Genomics:BGI Genomics, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July of 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.

Unveiling Microbiome Variations in Early and Late-Onset Colorectal Cancer | Springer Nature

BGI Genomics, a global leader in integrated precision medicine solutions, has established a new clinical laboratory at Uruguay's Parque de las Ciencias free trade zone. This facility is poised to become a regional hub, advancing preventive medicine across Latin America and utilizing advanced technology to facilitate early disease diagnosis.The inauguration was attended by Omar Paganini, Minister of Foreign Affairs; Elisa Facio, Minister of Industry, Energy and Mining; Karina Rando, Minister of Public Health, along with other national and departmental dignitaries. Dr. Yin Ye, CEO of BGI Group, the parent company of BGI Genomics, was also in attendance. Notably, Minister Rando had previously visited the site in August 2023, while Minister Facio met with Dr. Yin Ye in China in November 2023.<img src="https://cdn.it.bgi.com/source/040404fullribbon.jpg" alt="040404fullribbon.jpg" data-href="" style="">From left to right: Natalia Pereiras, Laboratory Director; Karina Rando, Minister of Public Health; Huang Yazhong, Chinese Ambassador for Uruguay; Omar Paganini, Minister of Foreign Affairs; Dr. Yin Ye, CEO of BGI Group; Elisa Facio, Minister of Industry, Energy and Mining; Wang Ruijun, Chairman of Guangdong Overseas Friendship Association; Marcelo Metediera, Mayor of Canelones. This laboratory, the first of its kind in the region, specializes in precision medicine applications. It is 1,000 square meters and dedicated exclusively to the company's operations.This facility boasts a Huo-Yan Air Laboratory equipped with seven cabins that cover the entire genetic testing process: sample handling, extraction, sequencing, analysis, quality control, and report generation. The facility also features an advanced heating, ventilation, and air conditioning (HVAC) system and unique design elements to prevent contamination between cabins.Currently, the laboratory employs Uruguayan technicians specializing in biochemistry and biotechnology. These technicians are supported by application experts from China who are providing training on the latest technology used by BGI Genomics.The company has developed the Next-Generation Sequencing (NGS) technology, which has revolutionized genomics and molecular biology. With this technology, BGI Genomics aims to make genetic testing more accessible and affordable, to support earlier diagnoses across Latin America.Elisa Facio, Minister of Industry, Energy and Mining, mentioned, "At the Ministry of Industry, Energy and Mining we are focused on promoting innovation, emerging technologies and science. Therefore, when BGI Genomics decided to launch its first Latin American laboratory in Uruguay, it was excellent news for our ministry and for the country. We understand that biotechnology is an economically booming sector, with a lot of potential, that is why we are making efforts to position the country in this field of science. The fact that this world leader in biotechnology, present in more than 100 countries worldwide, has decided to set up in Uruguay is a sign that we are on the right track."Natalia Pereiras, laboratory director, stated, "Our main goal is to bring these advanced diagnostic tools to the population at an affordable cost. By developing both the product and the methodology in-house, we can reduce costs significantly compared to other labs."Wu Liang, general manager for Latin America at BGI Genomics, highlighted Uruguay's strategic advantages, including its location near the Carrasco Airport and the benefits of operating within a free trade zone. "We are positioned to bring earlier diagnoses of genetic diseases to all of Latin America. Preventive medicine and technologies like pharmacogenetics are crucial for the future," he remarked.BGI Genomics also developed an extensive oncology portfolio. Among these offerings is the COLOTECT product utilizing Real-Time PCR technique, used for detecting colorectal cancer, which is the third most common type of cancer and the second leading cause of cancer death in Uruguay, following lung carcinoma. In addition, the SENTIS portfolio allows for the testing of 688 cancer-related genes from tumor biopsies, followed by testing 290 drugs that help select the most suitable treatment for the patient. These molecular biology techniques are valuable tools that can assist clinicians and are non-invasive.Another major focus of BGI Genomics is reproductive health, and among its products is NIFTY, which provides prenatal screening from the tenth week of gestation using a blood sample to analyze DNA. The conventional NIFTY test studies trisomy or the presence of an additional chromosome in pairs 13, 18, and 21, which are the most prevalent. This test detects certain microdeletions or losses of chromosomal material, as well as duplications. Additionally, the company developed NIFTY Pro, which is a more comprehensive test that can detect DiGeorge syndrome, among other disorders, caused by the deletion of a small part of chromosome 22.About BGI Genomics<a href="https://www.bgi.com/global" target="_blank">BGI Genomics</a>, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Its services cover more than 100 countries and regions, involving more than 2,300 medical institutions and 10,000 employees worldwide. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) officially began trading on the Shenzhen Stock Exchange.First published on: <a href="https://en.prnasia.com/releases/apac/bgi-genomics-leads-innovation-with-inaugural-clinical-lab-in-uruguay-444097.shtml" target="_blank">PR Newswire</a>

BGI Genomics Unveils First Cutting-Edge Clinical Lab in Uruguay

<img src="https://cdn.it.bgi.com/source/website+preview+crc.jpg" alt="website+preview+crc.jpg" data-href="" style="">Over recent decades, the incidence of colorectal cancer (CRC) in individuals under 50 years old, known as early-onset or young-onset CRC (YO-CRC), has been rising according to the <a href="https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21834" target="_blank">American Cancer Society</a>. Projections published on <a href="https://www.nature.com/articles/s41572-023-00432-7" target="_blank">Nature</a> suggest that by 2030, YO-CRC will constitute 11% of colon cancers and 23% of rectal cancers, with notable increases in the United States, Canada, and Australia.The diagnosis of colorectal cancer (CRC) among young adults aged between 19-39 was more likely to be dismissed or misdiagnosed with other diseases, such as inflammatory bowel disease. When a young patient is diagnosed with CRC, it is often at stage III or IV, which dramatically increases the cost and difficulties of treatment and potentially raises the risk of mortality.<img src="https://cdn.it.bgi.com/source/colotect+resized.jpg" alt="colotect+resized.jpg" data-href="" style="width: 100%;">Early screening and regular testing can be an effective way to prevent and treat CRC at an early stage. <a href="https://colotectglobal.com/" target="_blank">COLOTECT&trade;</a>, a non-invasive test that requires only a stool sample, is available for colorectal cancer screening and can provide medical professionals with evidence to support their diagnosis. Due to the increase in cases and misdiagnosis of CRC, raising awareness of colorectal cancer among young people and in society is urgently needed.Dramatically Increase Among Young while Decline for the ElderlyColorectal cancer should be tested at an earlier age, even though the official guideline is 45, according to the United States Preventive Services Task Force (USPSTF) and the American Cancer Society (ACS). While CRC incidence remains stable in people over 50 years of age in high-income countries, it is rising rapidly in those under 50 years of age. <img src="https://cdn.it.bgi.com/source/image755.png" alt="image755.png" data-href="" style="width: 100%;">The graph shows a sharp rise in colorectal cancer incidence among 20-39 year-olds and a relatively stable incidence rate among 40-49 year-olds. Source: National Institutes of Health: Young-onset colorectal cancer.Recent National Institutes of Health (NIH) <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589420/" target="_blank">studies</a> show a sharp rise in colorectal cancer (CRC) among 20–39-year-olds. This group has unique clinical and pathological traits. They differ from those seen in people aged 40-49. These findings suggest that the age threshold for colorectal cancer screening may change over time. In the United States, routine CRC screening currently begins at age 45, but as trends evolve, especially in the 45–50 age group, this starting age may be reconsidered to better address youth-onset CRC (YO-CRC). The increase in the incidence of colorectal cancer among young people raises the alarm for regular screening for colorectal health, even at younger ages. Some cases are asymptomatic, and often, symptoms are ignored for various reasons.Often Misdiagnosed and Symptoms Occur at Advanced<img src="https://cdn.it.bgi.com/source/image501.png" alt="image501.png" data-href="" style="width: 100%;">Nearly half of respondents aged under 30 do not have a primary care doctor. Source: KFF Health Tracking PollAccording to a 2018 <a href="https://www.kff.org/other/slide/one-fourth-of-adults-and-nearly-half-of-adults-under-30-dont-have-a-primary-care-doctor/ " target="_blank">KFF Health Tracking Poll</a>, one-fourth of adults and nearly half of those under the age of 30 do not have a primary care doctor. This lack of consistent healthcare means that when it comes to symptoms and cancer diagnosis, medical professionals might not be familiar with the patient’s past medical history, making it harder to provide an accurate diagnosis without additional screening support or access to the patient's previous medical records. <img src="https://cdn.it.bgi.com/source/image853.png" alt="image853.png" data-href="" style="width: 100%;">The Colorectal Cancer Alliance survey indicated that 54% of respondents, or 479 individuals, were misdiagnosed with different conditions. Source: Colorectal Cancer Alliance: Never Too Young Survey and Report.A <a href="https://colorectalcancer.org/resources-support/community-support/young-onset-support/never-too-young-survey-and-report" target="_blank">survey </a>by the Colorectal Cancer Alliance (CCA, 2020) reveals that young patients aged between 19-39 were more likely to have their concerns dismissed by doctors. The 54% of survey respondents were initially misdiagnosed. Around 75% of young colorectal cancer patients and survivors consulted at least two doctors before receiving a diagnosis, and 40% reported that their doctors ignored their symptoms and concerns. <img src="https://cdn.it.bgi.com/source/image879.png" alt="image879.png" data-href="" style="width: 100%;">Around 75% of respondents said they saw at least two different doctors before getting diagnosed with colorectal cancer. Source: Colorectal Cancer Alliance: Never Too Young Survey and Report.“The provider actually told me, ‘That’s the thing about you students — you have so much knowledge, but you know nothing about medicine,’” Shauna Nguyen told <a href="https://www.nbcnews.com/health/cancer/colon-cancer-young-people-describe-signs-ignored-rcna129838 " target="_blank">NBC News</a>. In 2016, then-28-year-old Nguyen, who was studying to become a physician assistant, suggested that her symptoms might indicate cancer. She added, “A little bit inside of me also just said, ‘Oh, your symptoms are nothing, Shauna.’” Often, patients are led to believe that a doctor's medical diagnosis is indisputable and should not be questioned, which can lead to the dismissal of early symptoms of CRC as overreactions.Symptomatic or NotMany believe that tumors or cancers only develop with symptoms, leading many patients to visit doctors only when feeling unwell. However, according to the <a href="https://colorectalcancer.org/resources-support/community-support/young-onset-support/never-too-young-survey-and-report" target="_blank">latest report</a> from the Colorectal Cancer Alliance (CCA, 2020), the majority (77%) of patients reported being in good or very good health before their diagnosis, with 21% affirming they were in good health. Kathryn Sisler shared her story with <a href="https://www.nbcnews.com/health/cancer/colon-cancer-young-people-describe-signs-ignored-rcna129838 " target="_blank">NBC News</a>, indicating that not all cases are symptomatic. <img src="https://cdn.it.bgi.com/source/image971.png" alt="image971.png" data-href="" style="width: 100%;">Of survey participants, 85% believed they led an active or very active lifestyle, while 15% replied that they were sedentary. Source: Colorectal Cancer Alliance: Never Too Young Survey and Report.At just 30 years old and aware of her family history, Kathryn was advised by her doctor to undergo a colonoscopy. Having lost her father to colorectal cancer, she was committed to maintaining her health. Adhering strictly to a plant-based diet, exercising five or six times a week, training for a half marathon, and teaching yoga in her community, she did everything by the book. Despite her efforts, she faced a dire diagnosis.The colonoscopy revealed she was at stage III of cancer, with her colon nearly obstructed by a tumor. Kathryn underwent surgery to remove the tumor and had a temporary ostomy—a surgical opening in the abdomen to allow waste to exit into an external bag. Fortunately, by the end of 2023, Kathryn had recovered well enough to resume her passion for yoga and running.From Awareness to Prevention The increasing incidence rate of CRC and the difficulties in diagnosing it among young people are raising the alarm for early and regular screenings for colorectal health. Although it's not yet clear why colorectal cancer is on the rise among younger individuals, experts are actively investigating potential factors, including diet, obesity, physical inactivity, smoking, alcohol consumption, and family history. Importantly, raising awareness of CRC in society and consulting a primary care doctor for regular screening tests can help protect you and your family from the risk of cancer. <img src="https://cdn.it.bgi.com/source/image163.png" alt="image163.png" data-href="" style="width: 100%;">Photo of Ingrid Hricová, a 54-year-old special education professional from Košice, Slovakia, who is a patient of COLOTECT™ and a fighter against colorectal cancer. Source: <a href="https://www.bgi.com/global/news/beating-colorectal-cancer-with-early-screening-and-detection" target="_blank">Story of Ingrid Hricová.</a>“My desire is that it [COLOTECT&trade;] will encourage people to get tested, to take preventive measures, and to take advantage of all the opportunities that modern medicine offers us,” says Ingrid Hricová, another CRC patient, in an interview, highlighting the need for preventive CRC screening.<a href="https://colotectglobal.com/" target="_blank">COLOTECT&trade;</a> a non-invasive home testing kit and a multi-target fecal DNA test, used alongside the Fecal Immunochemical Test (FIT), can be administered every 3 years for regular colorectal cancer screening. This approach helps in detecting gene mutations and potential risks of CRC at an early stage, even when symptoms are not present. <img src="https://cdn.it.bgi.com/source/website+preview+-+Jx+Tan+%282%29.jpg" alt="website+preview+-+Jx+Tan+%282%29.jpg" data-href="" style="width: 100%;">The recent findings highlight a worrying increase in yearly colorectal cancer rates among young adults, revealing a crucial need for improved awareness and proactive healthcare. Many patients struggle to receive accurate diagnoses, often facing initial misdiagnosis by healthcare providers. Regular screenings help prevent colorectal and other cancers. People of all ages should stay proactive about health, seek multiple doctor opinions if needed, and remind families to get annual check-ups for better health. When it comes to health, the sooner, the better. About BGI GenomicsBGI Genomics, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.Read more: <a href="https://www.bgi.com/global/news/bgi-genomics-2023-global-state-of-colorectal-cancer-awareness-report" target="_blank">BGI Genomics 2023 Global State of Colorectal Cancer Awareness Report</a><a href="https://www.bgi.com/global/news/beating-colorectal-cancer-with-early-screening-and-detection" target="_blank">Beating Colorectal Cancer with Early Screening and Detection: Patient's Voice</a>

Colorectal Cancer Strikes Younger Than Ever | BGI Insight

<img src="https://cdn.it.bgi.com/source/240410bannerresized.jpg" alt="240410bannerresized.jpg" data-href="" style="">The organizing committee of the ICG-19 is thrilled to announce the 19th International Conference on Genomics Thailand part (ICG-19-THA) will be held at Chulalongkorn University Hospital in Bangkok on May 18th and 19th, 2024.ICG-19-THA will continue to uphold the spirit of the Human Genome Project (HGP) - "Owned by All, Done by All, Shared by All," advocating for global and human-wide sharing, especially promoting international cooperation among developing countries.This year's conference promises to be very meaningful, featuring not only the traditional academic sessions of ICG but also introducing an intriguing forum - Transformation and Application in Longevity. This session will focus on how advancements in genetic technology can contribute to healthy aging in humans and further explore the profound impacts of this phenomenon on global economies, social structures, retirement systems, and ethical regulations. With global aging becoming a universal challenge, discussions on longevity economics are particularly pertinent, as they not only concern future economic development models but also touch upon the sustainability and equity of human societies.The session will emphasize promoting health span through scientific research and technological means while exploring the development potential and possibilities of longevity economics, providing new impetus for global economic development.The 19th International Conference on Genomics, with its broad international perspective, focuses on the latest genomic research while addressing significant issues in human society, demonstrating the power and charm of science, as well as scientists' profound concern for the future of humanity. We look forward to this scientific feast, anticipating it will bring new hope and possibilities for the future of humanity. &nbsp;1. Information<ul><li style="text-align: left;">Date: May 18-19, 2024 </li><li style="text-align: left;">Theme: Omics, Wellness and Longevity</li><li style="text-align: left;">Venue: Chulalongkorn University, Thailand</li><li style="text-align: left;">Language: English</li><li style="text-align: left;">Expected Audience: 300 participants</li></ul>2. Organizers<ul><li style="text-align: left;">Faculty of Medicine-Chulalongkorn University</li><li style="text-align: left;">BGI Group</li><li style="text-align: left;">Bangkok Genomics Innovation PCL (BKGI)</li><li style="text-align: left;">Harvard Business Review</li><li style="text-align: left;">Bumrungrad International Hospital &amp; VitalLife Scientific Wellness Center</li><li style="text-align: left;">ThaiOmics</li></ul>Operators: Hangzhou Bictimes Culture and Technology Co., Ltd3. Committee<ul><li style="text-align: left;">Chair of the Organizing Committee: Huanming Yang</li><li style="text-align: left;">Chair of the Academic Committee: Siqi Liu</li><li style="text-align: left;">Executive Chair of the Organizing Committee: Ye Yin</li><li style="text-align: left;">Co-chairs of the IIAB ( International Independent Advisory Board): Fred Dubee, Lars Bolund</li><li style="text-align: left;">Co-chairs of the ICG-19-THA: Fred Dubee, Vorasuk Shotelersuk, Nattiya Hirankarn</li><li style="text-align: left;">Co-chairs of the Transformation and Application in Longevity: Brian Kennedy, Guanghui Liu</li></ul>4. Program<table style="width: auto;"><tbody><tr><td colSpan="1" rowSpan="1" width="150">Time</td><td colSpan="1" rowSpan="1" width="423">Session</td></tr><tr><td colSpan="1" rowSpan="1" width="150">Saturday May 18, 2024</td><td colSpan="1" rowSpan="1" width="423">- Challenges and Recommendations in Establishing National Genomics Projects for Health - Rare Disease - Cancer Genomics - Traditional Medicine</td></tr><tr><td colSpan="1" rowSpan="1" width="150">Sunday May 19, 2024</td><td colSpan="1" rowSpan="1" width="423">- Transformation and Application in Longevity - Roundtable Forum: Longevity Economy</td></tr></tbody></table>5. Moderators and Speakers (In alphabetical order of speakers' last names. List continuously updated)<img src="https://cdn.it.bgi.com/source/240410icgparticipantsfirstresizedthird.jpg" alt="240410icgparticipantsfirstresizedthird.jpg" data-href="" style=""/><img src="https://cdn.it.bgi.com/source/240410icg19participantssecondresizedthird.jpg" alt="240410icg19participantssecondresizedthird.jpg" data-href="" style=""/>6. Registration Process:6.1: Registration Fee Standards<table style="width: auto;"><tbody><tr><td colSpan="1" rowSpan="1" width="173">Type</td><td colSpan="1" rowSpan="1" width="209">Early bird price Before May 18</td><td colSpan="1" rowSpan="1" width="186">On-site registration fee</td></tr><tr><td colSpan="1" rowSpan="1" width="173">Standard</td><td colSpan="1" rowSpan="1" width="209">999 CNY 5000 THB</td><td colSpan="1" rowSpan="1" width="186">1099 CNY 5500 THB</td></tr><tr><td colSpan="1" rowSpan="1" width="173">Student and BGI Staff</td><td colSpan="1" rowSpan="1" width="209">499 CNY 2500 THB</td><td colSpan="1" rowSpan="1" width="186">599 CNY 3000 THB</td></tr></tbody></table>*Note: Students and BGI staffs are entitled to a 50% discount with a valid ID. The BGI staff card is only used for registration and cannot be used as a proof of attendance.6.2 Payment Methods:6.2.1 Alipay or WeChat Pay <img src="https://cdn.it.bgi.com/source/240410paymentmethod.jpg" alt="240410paymentmethod.jpg" data-href="" style=""/>Please scan the QR code above to pay the registration fee*Remittance Note: For those who register and pay the fee through Alipay or WeChat Pay, please make sure to upload the picture of the remittance voucher after paying the fee so that you can check and inquire about invoicing.6.2.2 Bank Transfer (THB Only)Account name: Bangkok Genomics Innovation Public Company LimitedAccount number: 425-171934-1Bank: Siam Commercial Bank PCL(SWIFT CODE): SICOTHBKBranch: Big C Rama 4*Remittance Note: Please make sure to indicate "Remitter's Name + ICG-19-THA", and send the remittance voucher, personal information of the remittance, including name, contact information and student ID card or BGI Staff card if available, and invoice/ticket information to the following e-mail address: icg19@bictimes.cn6.2.3 Please note：(1) The registration time is based on the actual payment time, and the on-site payment is based on the on-site payment price.(2) Participants who have paid the fee and are unable to attend the conference for any reason, please apply to the conference organizer. The remaining balance will be refunded after deducting 200 CNY handling fee.(3) Invoice issuance and collection: Pay attention to check the electronic invoice through the registered email address before and after 10 working days after the successful payment, and the invoice for on-site registration will be issued within 15 working days after the meeting.(4) The registration fee includes 2-day lunch. Transportation and accommodation costs are at your own expense.7. ExhibitingTime: May 18-19, 2024Venue: Chulalongkorn University, ThailandFor more information, please contact: Ms. Wang Jing - &nbsp;<a href="mailto:wangjing@bictimes.cn" target="">wangjing@bictimes.cn</a>8. Contact UsFor more information about registration, invoicing, exhibition and participation, please contact: <a href="mailto:icg19@bictimes.cn" target="">icg19@bictimes.cn</a>

News

Study Reveals How Fetal Ear Shape Could Signal Rare Genetic Condition | BGI Insight

BGI Genomics’ First African Public Health Initiative: Supporting Cervical Cancer Screening for 20,000 Rwandans

The Second Announcement of the ICG-19-THA

Study Reveals How Fetal Ear Shape Could Signal Rare Genetic Condition | BGI Insight

BGI Genomics’ First African Public Health Initiative: Supporting Cervical Cancer Screening for 20,000 Rwandans

The Second Announcement of the ICG-19-THA

Navigating the Complexities of Data Security in Biotechnology | BGI Perspectives

Unveiling Microbiome Variations in Early and Late-Onset Colorectal Cancer | Springer Nature

BGI Genomics Unveils First Cutting-Edge Clinical Lab in Uruguay

Colorectal Cancer Strikes Younger Than Ever | BGI Insight

Unlocking Longevity and Innovation: Join Us at ICG-19 in Bangkok